A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions

Clamp Study

Interventions

DRUG

GP-40081

biphasic insulin aspart 30 in doses 0.4 IU/kg

DRUG

NovoMix® 30 Penfill®

biphasic insulin aspart 30 in doses 0.4 IU/kg

Trial Locations (2)

Endocrinology Research Centre, Moscow

Almazov National Medical Research Centre, Saint Petersburg